Literature DB >> 24179109

CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads.

Amie L Meditz1, Joy M Folkvord, Ngan H Lyle, Kristina Searls, Yolanda S Lie, Eoin P Coakley, Martin McCarter, Samantha Mawhinney, Elizabeth Connick.   

Abstract

BACKGROUND: Human immunodeficiency virus type 1 (HIV-1)-infected women have lower viral loads than men but similar rates of disease progression. We hypothesized that sex-based differences in CCR5 expression mediate viral load differences.
METHODS: CCR5 was analyzed by flow cytometry in disaggregated lymph node cells from untreated HIV-1-infected women (n = 28) and men (n = 27). The frequencies of HIV-1 RNA-producing cells in the lymph node were determined by in situ hybridization. Linear and generalized linear regression models were used.
RESULTS: The percentage of CCR5(+)CD3(+)CD4(+) cells was lower in women (mean, 12%) than men (mean, 16%; P = .034). Neither the percentage of CCR5(+)CD3(+)CD4(+) cells nor the CCR5 density predicted viral load or HIV-1 RNA-producing lymph node cells (P ≥ .24), after adjusting for CD4(+) T-cell count, race, and age. Women had marginally fewer HIV-1 RNA-producing cells (mean, 0.21 cells/mm(2)) than men (mean, 0.44 cells/mm(2); P = .046). After adjusting for the frequency of HIV-1 RNA-producing cells and potential confounders, the viral load in women were 0.46 log10 copies/mL lower than that in men (P = .018).
CONCLUSIONS: Reduced lymph node CCR5 expression in women did not account for the viral load difference between sexes. CCR5 expression did not predict viral load or frequencies of HIV-1 RNA-producing cells, indicating that physiologic levels of CCR5 do not limit HIV-1 replication in lymph node. Less plasma virus was associated with each HIV-1 RNA-producing cell in women as compared to men, suggesting that women may either produce fewer virions per productively infected cell or more effectively clear extracellular virus.

Entities:  

Keywords:  CCR5; HIV-1; Immune activation; Lymph node; Sex differences

Mesh:

Substances:

Year:  2013        PMID: 24179109      PMCID: PMC3935472          DOI: 10.1093/infdis/jit575

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Sex differences in HIV-1 viral load due to sex difference in CCR5 expression.

Authors:  P Portales; J Clot; P Corbeau
Journal:  Ann Intern Med       Date:  2001-01-02       Impact factor: 25.391

2.  Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion.

Authors:  E Connick; R L Schlichtemeier; M B Purner; K M Schneider; D M Anderson; S MaWhinney; T B Campbell; D R Kuritzkes; J M Douglas; F N Judson; R T Schooley
Journal:  J Infect Dis       Date:  2001-11-13       Impact factor: 5.226

Review 3.  Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics.

Authors:  C M Hogan; S M Hammer
Journal:  Ann Intern Med       Date:  2001-05-15       Impact factor: 25.391

4.  Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.

Authors:  T R Sterling; D Vlahov; J Astemborski; D R Hoover; J B Margolick; T C Quinn
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women.

Authors:  Amie L Meditz; Kerrie L Moreau; Samantha MaWhinney; Wendolyn S Gozansky; Kelsey Melander; Wendy M Kohrt; Margaret E Wierman; Elizabeth Connick
Journal:  J Acquir Immune Defic Syndr       Date:  2012-03-01       Impact factor: 3.731

6.  CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression.

Authors:  J Reynes; P Portales; M Segondy; V Baillat; P André; O Avinens; M C Picot; J Clot; J F Eliaou; P Corbeau
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

7.  CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1.

Authors:  J Reynes; P Portales; M Segondy; V Baillat; P André; B Réant; O Avinens; G Couderc; M Benkirane; J Clot; J F Eliaou; P Corbeau
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

8.  Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count.

Authors:  Beatriz Grinsztejn; Laura Smeaton; Ronald Barnett; Karin Klingman; James Hakim; Timothy Flanigan; N Kumarasamy; Thomas Campbell; Judith Currier
Journal:  Antivir Ther       Date:  2011

9.  Gender difference in HIV RNA levels: a meta-analysis of published studies.

Authors:  Sonia Napravnik; Charles Poole; James C Thomas; Joseph J Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2002-09-01       Impact factor: 3.731

10.  Does patient sex affect human immunodeficiency virus levels?

Authors:  Monica Gandhi; Peter Bacchetti; Paolo Miotti; Thomas C Quinn; Fulvia Veronese; Ruth M Greenblatt
Journal:  Clin Infect Dis       Date:  2002-07-02       Impact factor: 9.079

View more
  7 in total

1.  Follicular Regulatory T Cells Are Highly Permissive to R5-Tropic HIV-1.

Authors:  Shannon M Miller; Brodie Miles; Kejun Guo; Joy Folkvord; Amie L Meditz; Martin D McCarter; David N Levy; Samantha MaWhinney; Mario L Santiago; Elizabeth Connick
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

2.  Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.

Authors:  Amie L Meditz; Claire Palmer; Julie Predhomme; Kristina Searls; Becky Kerr; Sharon Seifert; Patricia Caraway; Edward M Gardner; Samantha MaWhinney; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-10       Impact factor: 2.205

3.  Distinct patterns of Bcl-2 expression occur in R5- and X4-tropic HIV-1-producing lymphoid tissue cells infected ex vivo.

Authors:  Michelle K Haas; David N Levy; Joy M Folkvord; Elizabeth Connick
Journal:  AIDS Res Hum Retroviruses       Date:  2014-10-29       Impact factor: 2.205

4.  Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.

Authors:  Eileen P Scully; Evgenia Aga; Athe Tsibris; Nancie Archin; Kate Starr; Qing Ma; Gene D Morse; Kathleen E Squires; Bonnie J Howell; Guoxin Wu; Lara Hosey; Scott F Sieg; Lynsay Ehui; Francoise Giguel; Kendyll Coxen; Curtis Dobrowolski; Monica Gandhi; Steve Deeks; Nicolas Chomont; Elizabeth Connick; Catherine Godfrey; Jonathan Karn; Daniel R Kuritzkes; Ronald J Bosch; Rajesh T Gandhi
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999

5.  Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.

Authors:  Eileen P Scully; Monica Gandhi; Rowena Johnston; Rebecca Hoh; Ainsley Lockhart; Curtis Dobrowolski; Amélie Pagliuzza; Jeffrey M Milush; Christopher A Baker; Valerie Girling; Arlvin Ellefson; Robert Gorelick; Jeffrey Lifson; Marcus Altfeld; Galit Alter; Marcelle Cedars; Ajantha Solomon; Sharon R Lewin; Jonathan Karn; Nicolas Chomont; Peter Bacchetti; Steven G Deeks
Journal:  J Infect Dis       Date:  2019-03-15       Impact factor: 5.226

6.  Tissue-specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART-treated women.

Authors:  Sara Moron-Lopez; Guorui Xie; Peggy Kim; David A Siegel; Sulggi Lee; Joseph K Wong; Jennifer C Price; Najwa Elnachef; Ruth M Greenblatt; Phyllis C Tien; Nadia R Roan; Steven A Yukl
Journal:  J Int AIDS Soc       Date:  2021-07       Impact factor: 5.396

7.  CCR5-Δ32 polymorphism: a possible protective factor for post-stroke depressive symptoms.

Authors:  Oren Tene; Hen Hallevi; Jeremy Molad; Saly Usher; Estelle Seyman; Natan M Bornstein; Shani Shenhar-Tsarfaty; Einor Ben Assayag
Journal:  J Psychiatry Neurosci       Date:  2021-07-22       Impact factor: 6.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.